Verrica (VRCA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$30.3M

Revenue (quarter)

$5.9M

Revenue growth (year over year)

−53.85%

Gross profit (trailing twelve months)

$26.0M

Gross margin

85.89%

Net income (trailing twelve months)

−$31.2M

Net income (quarter)

−$13.2M

Net income growth (year over year)

−6547.55%

Net margin

−102.84%

Return on equity

—

EPS (trailing twelve months)

−$1.74

Book value per share

$0.25

P/E (trailing twelve months)

—

Price to book

15.08

Debt to assets

88.04%

Payout ratio

—

Dividend yield

—

Company profile

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

• Is Verrica (VRCA) profitable?

  No. Verrica reported a net loss of $31.2M over the trailing twelve months.

• How much revenue does Verrica (VRCA) make?

  Verrica generated $30.3M in revenue over the trailing twelve months, down 53.85% year over year.

• How do I buy stock in Verrica (VRCA)?

  VRCA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.